Dupixent Denied for Asthma? How to Appeal Your Insurance Denial

Dupixent (dupilumab) is FDA-approved as an add-on maintenance treatment for moderate-to-severe asthma in patients aged 6 and older, with particular effectiveness in patients with an eosinophilic phenotype or who depend on oral corticosteroids. Despite its proven ability to reduce asthma exacerbations, emergency visits, and oral steroid use, insurance companies frequently deny Dupixent for asthma due to step therapy requirements and competing biologic options. Here's how to fight back.

What Dupixent Does for Asthma and Why Patients Need It

Dupixent blocks IL-4 and IL-13 signaling — two cytokines central to the type 2 (T2) inflammatory response driving eosinophilic and allergic asthma. In clinical trials (LIBERTY ASTHMA QUEST and VENTURE), Dupixent reduced severe asthma exacerbations by up to 67% and allowed many oral corticosteroid (OCS)-dependent patients to completely eliminate or dramatically reduce their OCS use.

For patients with severe, uncontrolled asthma who are not achieving control with inhaled steroids (ICS), long-acting beta-agonists (LABA), and other controller medications, Dupixent addresses the underlying inflammatory driver of their disease rather than just providing symptom relief.

Particularly important: Dupixent is uniquely suited to patients with overlapping eosinophilic asthma and atopic dermatitis, nasal polyps, or eosinophilic esophagitis — conditions that share the same IL-4/IL-13 axis.

Common Denial Reasons for Dupixent for Asthma

Step therapy / other biologics first: Insurers often require patients to try a different asthma biologic before Dupixent. Competing agents — Nucala (mepolizumab), Fasenra (benralizumab), Cinqair (reslizumab), and Xolair (omalizumab) — are sometimes required as prior steps. Plans may prefer whichever agent is on their formulary.

Eosinophil threshold not documented: Many PA criteria require a blood eosinophil count above a specific threshold (commonly ≥150 or ≥300 cells/µL) for asthma biologic coverage. If this isn't documented in recent labs, the PA may be denied.

Severity threshold not met: Plans may require documentation of uncontrolled moderate-to-severe asthma — typically defined as at least 2 exacerbations per year requiring systemic steroids, or OCS dependence. If exacerbation history isn't well-documented, the claim may be denied.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization not submitted correctly: Missing documentation of eosinophil counts, exacerbation frequency, or prior step therapy often leads to automatic PA denial.

Not the plan's preferred biologic: Some plans prefer Fasenra or Nucala for eosinophilic asthma patients over Dupixent.

Step-by-Step: How to Appeal a Dupixent Asthma Denial

Step 1: Get the specific denial reason. Know whether you're fighting a step therapy requirement, an eosinophil threshold issue, or a severity documentation gap.

Step 2: Document your eosinophil count. Pull recent CBC with differential results. If your eosinophil count is ≥150 or ≥300, highlight this prominently. If it's lower, focus on OCS dependence as the alternative qualifying criterion.

Step 3: Document your asthma exacerbation history. Include dates of systemic steroid bursts, ER visits, hospitalizations, and urgent care visits for asthma in the past 12–24 months.

Step 4: Document your current controller medication regimen. Show that you're on or have trialed high-dose ICS/LABA and other appropriate controller therapies. If long-acting muscarinic antagonist (LAMA) or theophylline was used, document that too.

Step 5: Have your pulmonologist or allergist write a Letter of Medical Necessity. The LMN should explain your asthma phenotype, eosinophil level, OCS use, exacerbation history, and why Dupixent is the appropriate biologic choice for your specific situation.

Step 6: File the internal appeal and request peer-to-peer review.

Step 7: File an external appeal if the internal appeal is denied.

What to Include in Your Dupixent Asthma Appeal Letter

• Policy number, member ID, claim reference, and denial date
• Dupixent indication: add-on maintenance for moderate-to-severe asthma
• Blood eosinophil count (CBC with differential, date of test)
• Spirometry/lung function data (FEV1, FEV1/FVC)
• Asthma exacerbation history: dates, severity, treatment required
• List of current and prior asthma medications with dates and outcomes
• OCS dependence documentation if applicable
• Any comorbid conditions: atopic dermatitis, nasal polyps, allergic rhinitis, EoE
• Letter of Medical Necessity from pulmonologist or allergist/immunologist
• GINA (Global Initiative for Asthma) guideline and FDA approval references
• Request for peer-to-peer review

Success Tips for Dupixent Asthma Appeals

Lead with the eosinophil count if it's high. A blood eosinophil count ≥300 cells/µL is the strongest qualifier for all asthma biologics and is the population where Dupixent shows the most dramatic benefit. Make this the first piece of clinical data in your appeal.

Emphasize OCS dependence if applicable. Chronic oral corticosteroid use carries severe long-term risks — osteoporosis, adrenal suppression, diabetes, Cushing's syndrome. Insurers respond to arguments that Dupixent can replace OCS use, because the downstream cost of OCS complications is enormous.

Argue for phenotype-specific selection. If you have both asthma and atopic dermatitis or nasal polyps, Dupixent is uniquely positioned to treat multiple conditions simultaneously through a single biologic. This is a strong argument for choosing Dupixent over eosinophil-targeted biologics like Nucala or Fasenra.

Use an allergist or pulmonologist. Specialty physician support in the appeal process — especially for a peer-to-peer review — significantly improves outcomes.

Fight Back With ClaimBack

Asthma that isn't controlled by standard medications deserves advanced biologic treatment. An insurance denial shouldn't keep you from a therapy that can reduce your risk of life-threatening attacks. ClaimBack helps you navigate the appeal process with confidence.

Start your asthma appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeals